SCHEMBL3159571

SCHEMBL3159571

O=C(NCc1ccc(C(F)(F)F)cc1)c1ccc(S(=O)(=O)Nc2nccs2)c(Cl)c1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 12/20 0.75
SCN5A Q14524 4/20 0.65
SCN9A Q15858 4/20 0.65
SCN1A P35498 3/20 0.65
SCN8A Q9UQD0 3/20 0.65
SCN2A Q99250 2/20 0.65
SCN10A Q9Y5Y9 2/20 0.65
KCNH2 Q12809 1/20 0.65
KDM1A O60341 1/20 0.47
HDAC1 Q13547 1/20 0.47
USP2 O75604 1/20 0.45
MAPT P10636 1/20 0.45
ESR2 Q92731 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NAMPT P43490 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
EPHX2 P34913 1/20 0.43
NR1H4 Q96RI1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13448136 0.94 SCN3A (0.65) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL3165836 0.90 SCN3A (0.62) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL3166193 0.90 SCN3A (0.76) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL3161293 0.89 SCN3A (0.75) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL3162733 0.88 SCN3A (0.68) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL3160783 0.88 SCN3A (0.68) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL3163178 0.87 SCN3A (0.66) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL3171480 0.86 SCN3A (0.71) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL3159993 0.86 SCN3A (0.68) SCN3ASCN5ASCN9ASCN1ASCN8A
SCHEMBL13452602 0.86 SCN3A (1.00) SCN3ASCN5ASCN9ASCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN5A 15/4885SCN9A 51/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN5A 15/4885SCN9A 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.